Hospital & Healthcare Services · Founded 2019 · www.krmayurvedaindia.com · NSE · ISIN INE1MTV01019
No Notes Added Yet
Business
KRM Ayurveda Ltd. operates in the Ayurvedic healthcare segment within India. Its core business likely revolves around providing traditional Ayurvedic medical services and potentially related products. This could include patient consultations, therapeutic treatments, wellness programs, and the sale of Ayurvedic medicines, supplements, or personal care products. The company primarily generates revenue through fees for its services (consultations, treatments) and the sales of its Ayurvedic product range.
Revenue Mix
Specific revenue mix is not available. However, potential key segments would include:
Healthcare Services: Consultations, diagnostic services (if applicable), inpatient and outpatient treatments (e.g., Panchakarma therapies, specialized treatments).
Product Sales: Manufacturing and sale of proprietary Ayurvedic medicines, classical formulations, dietary supplements, and potentially personal care or wellness products.
Wellness & Education: Offering wellness programs, retreats, and educational courses related to Ayurveda.
The relative contribution of these segments would depend on the company's operational focus (e.g., primarily clinics, a hospital, or product manufacturing).
Industry
KRM Ayurveda Ltd. operates within the Hospital & Healthcare Services sector, specifically targeting the Ayurvedic healthcare industry in India. This industry is highly fragmented, comprising numerous small clinics, individual practitioners, and a growing number of organized players, including large pharmaceutical companies and consumer goods giants with Ayurvedic product lines (e.g., Dabur, Himalaya, Patanjali, Baidyanath). The market is characterized by increasing consumer interest in natural and holistic wellness solutions. KRM Ayurveda likely positions itself as a provider of authentic Ayurvedic treatments and quality products, potentially carving out a niche based on specialization, regional presence, or specific product offerings.
MOAT
For an Ayurvedic company, potential competitive advantages (moats) often stem from:
Brand Reputation & Trust: A strong brand built on the efficacy and authenticity of treatments and products, fostering patient loyalty. This is crucial in traditional medicine.
Clinical Expertise: A team of highly qualified and experienced Ayurvedic practitioners who can deliver superior outcomes.
Proprietary Formulations/Treatments: Unique or highly effective Ayurvedic formulations or treatment protocols developed through R&D or extensive clinical practice.
Quality Control: Rigorous standards in sourcing raw materials and manufacturing processes for products.
Network Effect: If it establishes a wide chain of clinics/hospitals, though this is less common for specialized Ayurvedic players initially.
Without further information, it is difficult to ascertain the strength of KRM Ayurveda's moat, but its success will largely depend on building and maintaining a strong reputation for efficacy and trust.
Growth Drivers
Increasing Demand for Traditional Medicine: Growing global and domestic preference for natural, holistic, and preventive healthcare, especially post-pandemic.
Wellness Tourism: India's rising prominence as a destination for Ayurvedic treatments and wellness retreats.
Government Support: Initiatives by the Indian government to promote AYUSH (Ayurveda, Yoga & Naturopathy, Unani, Siddha, and Homoeopathy) systems.
Lifestyle Diseases: Ayurveda's potential role in managing chronic lifestyle-related diseases is drawing more attention.
Market Expansion: Opening new clinics, hospitals, or expanding product distribution channels across India or internationally.
Product Innovation: Introducing new or improved Ayurvedic products based on research and consumer needs.
Risks
Intense Competition: Significant competition from both organized (large FMCG/pharma players) and unorganized players in the Ayurvedic market.
Regulatory Changes: Potential changes in AYUSH regulations, quality control standards, or labeling requirements that could impact operations or product formulations.
Reputation Risk: Any negative perception regarding the efficacy or safety of Ayurvedic treatments or products could severely impact public trust and demand.
Talent Scarcity: Challenges in attracting and retaining highly skilled and experienced Ayurvedic practitioners.
Raw Material Sourcing: Dependency on specific herbs and natural ingredients, making it susceptible to supply chain disruptions, price volatility, and quality control issues.
Standardization Challenges: Difficulty in standardizing Ayurvedic treatments and product efficacy, which can affect wider acceptance and scientific validation.
Management & Ownership
Specific details regarding promoters, management quality, and ownership structure are not available. In many Indian companies, particularly in traditional sectors, the business is often promoter-led, with the vision and operational expertise of the founding family or individuals playing a crucial role. The success of KRM Ayurveda would largely depend on the management's ability to navigate a competitive and evolving market, maintain the authenticity and quality of its offerings, and execute growth strategies effectively.
Outlook
KRM Ayurveda Ltd. operates in a promising segment of the Indian healthcare market, driven by increasing consumer preference for traditional and holistic wellness solutions. The overall demand for Ayurvedic services and products is on an upward trajectory, supported by growing health consciousness and government initiatives. However, the company faces significant challenges, primarily from intense competition (including well-capitalized established brands), the need to consistently maintain high standards of quality and authenticity, and navigating evolving regulatory landscapes. Its success will hinge on its ability to build a strong, trusted brand, differentiate its offerings, ensure consistent efficacy of its treatments and products, and effectively scale its operations while retaining its core values.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|
| Net Sales | 89 | 67 | 77 | |
| Other Income | 0 | 0 | 0 | |
| Total Income | 89 | 68 | 77 | |
| Total Expenditure | 78 | 60 | 57 | |
| Operating Profit | 11 | 8 | 20 | |
| Interest | 1 | 2 | 2 | |
| Depreciation | 1 | 1 | 1 | |
| Exceptional Income / Expenses | 0 | 0 | 0 | |
| Profit Before Tax | 10 | 5 | 16 | |
| Provision for Tax | 2 | 1 | 4 | |
| Profit After Tax | 8 | 3 | 12 | |
| Adjustments | 0 | 0 | 0 | |
| Profit After Adjustments | 8 | 3 | 12 | |
| Adjusted Earnings Per Share | 5.1 | 2.3 | 8.1 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 15% | 0% | 0% | 0% |
| Operating Profit CAGR | 150% | 0% | 0% | 0% |
| PAT CAGR | 300% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | NA% | NA% | NA% | NA% |
| ROE Average | 68% | 64% | 64% | 64% |
| ROCE Average | 42% | 34% | 34% | 34% |
| #(Fig in Cr.) | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Shareholder's Funds | 8 | 12 | 24 |
| Minority's Interest | 0 | 0 | 0 |
| Borrowings | 18 | 21 | 19 |
| Other Non-Current Liabilities | 0 | 0 | 1 |
| Total Current Liabilities | 13 | 11 | 24 |
| Total Liabilities | 39 | 44 | 67 |
| Fixed Assets | 23 | 23 | 27 |
| Other Non-Current Assets | 0 | 0 | 1 |
| Total Current Assets | 16 | 21 | 39 |
| Total Assets | 39 | 44 | 67 |
| #(Fig in Cr.) | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Opening Cash & Cash Equivalents | 1 | 0 | 1 |
| Cash Flow from Operating Activities | 4 | -1 | -0 |
| Cash Flow from Investing Activities | -23 | -0 | -4 |
| Cash Flow from Financing Activities | 19 | 1 | 6 |
| Net Cash Inflow / Outflow | 0 | 0 | 2 |
| Closing Cash & Cash Equivalent | 1 | 1 | 2 |
| # | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Earnings Per Share (Rs) | 5.07 | 2.27 | 8.06 |
| CEPS(Rs) | 5.49 | 2.95 | 8.76 |
| DPS(Rs) | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 5.58 | 7.85 | 15.92 |
| Core EBITDA Margin(%) | 12.53 | 11.33 | 25.44 |
| EBIT Margin(%) | 11.91 | 10.43 | 24.6 |
| Pre Tax Margin(%) | 11.3 | 7.04 | 21.34 |
| PAT Margin (%) | 8.51 | 5.08 | 15.8 |
| Cash Profit Margin (%) | 9.23 | 6.6 | 17.17 |
| ROA(%) | 19.26 | 8.19 | 21.86 |
| ROE(%) | 90.82 | 33.88 | 67.86 |
| ROCE(%) | 37.67 | 22.17 | 41.83 |
| Receivable days | 31.72 | 36.13 | 42.11 |
| Inventory Days | 2.76 | 5.77 | 21.8 |
| Payable days | 100.32 | 163.45 | 176.74 |
| PER(x) | 0 | 0 | 0 |
| Price/Book(x) | 0 | 0 | 0 |
| Dividend Yield(%) | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.22 | 0.34 | 0.38 |
| EV/Core EBITDA(x) | 1.75 | 2.84 | 1.47 |
| Net Sales Growth(%) | 0 | -24.79 | 13.99 |
| EBIT Growth(%) | 0 | -34.15 | 168.79 |
| PAT Growth(%) | 0 | -55.09 | 254.53 |
| EPS Growth(%) | 0 | -55.09 | 254.53 |
| Debt/Equity(x) | 2.38 | 1.97 | 1.31 |
| Current Ratio(x) | 1.18 | 1.84 | 1.66 |
| Quick Ratio(x) | 1.13 | 1.71 | 1.33 |
| Interest Cover(x) | 19.26 | 3.07 | 7.56 |
| Total Debt/Mcap(x) | 0 | 0 | 0 |
| # | Mar 2026 |
|---|---|
| Promoter | 69.15 |
| FII | 3.86 |
| DII | 3.16 |
| Public | 23.83 |
| Others | 0 |
| Total | 100 |
| # | Mar 2026 |
|---|---|
| Promoter | 1.47 |
| FII | 0.08 |
| DII | 0.07 |
| Public | 0.51 |
| Others | 0 |
| Total | 2.13 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +15% | — | — | — |
| Operating Profit CAGR | +150% | — | — | — |
| PAT CAGR | +300% | — | — | — |
| Share Price CAGR | — | — | — | — |
| ROE Average | +68% | +64% | +64% | +64% |
| ROCE Average | +42% | +34% | +34% | +34% |
| # | Mar 2026 |
|---|---|
| Promoter | 69.15 |
| FII | 3.86 |
| DII | 3.16 |
| Public | 30.85 |
| Others | 0 |
| Total | 100 |
| # | Mar 2026 |
|---|---|
| Promoter | 1.47 |
| FII | 0.08 |
| DII | 0.07 |
| Public | 0.66 |
| Others | 0 |
| Total | 2.13 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.